Cue Biopharma names Shao‑Lee Lin CEO and licenses new allergy asset from Taiwan and China
read at Endpoints ↗DealPositive
Cue Biopharma announced a reboot, bringing in biotech veteran Shao‑Lee Lin as its new chief executive.
Lin, founder of Acelyrin, will lead the Boston‑based company as it expands its pipeline.
The company also disclosed a licensing agreement for an allergy drug candidate that was discovered in Taiwan and further developed in mainland China.
The move signals Cue’s strategy to broaden its portfolio and leverage cross‑border collaborations.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Acelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China”
read at Endpoints ↗93 words · retrieved May 1
comments(0)
5-min edit window · permanent after that